CN107847437B - 用于治疗疼痛的塞来昔布口服组合物 - Google Patents

用于治疗疼痛的塞来昔布口服组合物 Download PDF

Info

Publication number
CN107847437B
CN107847437B CN201680031177.5A CN201680031177A CN107847437B CN 107847437 B CN107847437 B CN 107847437B CN 201680031177 A CN201680031177 A CN 201680031177A CN 107847437 B CN107847437 B CN 107847437B
Authority
CN
China
Prior art keywords
composition
celecoxib
pain
minutes
auc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680031177.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107847437A (zh
Inventor
安基特·巴赫提
毕扬·库马尔·帕蒂赫
萨普瑞缇哈·瓦卡达
拉杰夫·辛格·拉古凡什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Priority to CN202311387716.7A priority Critical patent/CN117547528A/zh
Priority to CN202111630363.XA priority patent/CN114209707A/zh
Publication of CN107847437A publication Critical patent/CN107847437A/zh
Application granted granted Critical
Publication of CN107847437B publication Critical patent/CN107847437B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201680031177.5A 2015-05-28 2016-05-27 用于治疗疼痛的塞来昔布口服组合物 Active CN107847437B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202311387716.7A CN117547528A (zh) 2015-05-28 2016-05-27 用于治疗疼痛的塞来昔布口服组合物
CN202111630363.XA CN114209707A (zh) 2015-05-28 2016-05-27 用于治疗疼痛的塞来昔布口服组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN2682/CHE/2015 2015-05-28
IN2682CH2015 2015-05-28
IN6614/CHE/2015 2015-12-10
IN6614CH2015 2015-12-10
PCT/US2016/034844 WO2016191744A1 (en) 2015-05-28 2016-05-27 Oral composition of celecoxib for treatment of pain

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202311387716.7A Division CN117547528A (zh) 2015-05-28 2016-05-27 用于治疗疼痛的塞来昔布口服组合物
CN202111630363.XA Division CN114209707A (zh) 2015-05-28 2016-05-27 用于治疗疼痛的塞来昔布口服组合物

Publications (2)

Publication Number Publication Date
CN107847437A CN107847437A (zh) 2018-03-27
CN107847437B true CN107847437B (zh) 2024-03-26

Family

ID=56137539

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201680031177.5A Active CN107847437B (zh) 2015-05-28 2016-05-27 用于治疗疼痛的塞来昔布口服组合物
CN202311387716.7A Pending CN117547528A (zh) 2015-05-28 2016-05-27 用于治疗疼痛的塞来昔布口服组合物
CN202111630363.XA Pending CN114209707A (zh) 2015-05-28 2016-05-27 用于治疗疼痛的塞来昔布口服组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202311387716.7A Pending CN117547528A (zh) 2015-05-28 2016-05-27 用于治疗疼痛的塞来昔布口服组合物
CN202111630363.XA Pending CN114209707A (zh) 2015-05-28 2016-05-27 用于治疗疼痛的塞来昔布口服组合物

Country Status (12)

Country Link
US (7) US9572819B2 (cg-RX-API-DMAC7.html)
EP (1) EP3302429A1 (cg-RX-API-DMAC7.html)
JP (1) JP6605047B2 (cg-RX-API-DMAC7.html)
KR (1) KR101994129B1 (cg-RX-API-DMAC7.html)
CN (3) CN107847437B (cg-RX-API-DMAC7.html)
AU (2) AU2016267685A1 (cg-RX-API-DMAC7.html)
CA (1) CA2987272C (cg-RX-API-DMAC7.html)
EA (1) EA038013B1 (cg-RX-API-DMAC7.html)
MX (1) MX384044B (cg-RX-API-DMAC7.html)
NZ (1) NZ737561A (cg-RX-API-DMAC7.html)
RU (1) RU2708254C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016191744A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847437B (zh) * 2015-05-28 2024-03-26 瑞迪博士实验室有限公司 用于治疗疼痛的塞来昔布口服组合物
CN119055585A (zh) 2016-05-27 2024-12-03 雷迪博士实验室有限公司 用于治疗疼痛的塞来昔布口服组合物
US11770123B2 (en) 2018-01-05 2023-09-26 Darfon Electronics Corp. Optical keyswitch comprising a keycap having a light transmission area and a keycap projection area projected on a circuit board
US11108393B2 (en) 2018-01-05 2021-08-31 Darfon Electronics Corp. Optical keyswitch triggered by support mechanism having at least one rotatable frame enable a protrusion to move along with a key cap
CA3144079A1 (en) 2020-12-28 2022-06-28 Biodelivery Sciences International, Inc. Methods of treating pain
US11735379B2 (en) 2021-04-07 2023-08-22 Darfon Electronics Corp. Keyswitch assembly
US11721500B2 (en) 2021-04-07 2023-08-08 Darfon Electronics Corp. Keyswitch assembly and support mechanism thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078724A1 (en) * 2000-04-18 2001-10-25 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2
WO2004047752A2 (en) * 2002-11-26 2004-06-10 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
WO2010150144A2 (en) * 2009-06-25 2010-12-29 Wockhardt Research Centre Low dose pharmaceutical compositions of celecoxib

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
DE69422306D1 (de) 1993-11-30 2000-01-27 Searle & Co Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5993858A (en) 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
US6531139B1 (en) 1997-07-29 2003-03-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
EP2127642A3 (en) 1998-08-13 2010-02-24 Cima Labs, Inc. Microemulsions as solid dosage forms for oral administration
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
JP2002531515A (ja) 1998-12-11 2002-09-24 ファーマソリューションズ・インコーポレイテッド 水に難溶性の薬剤のための自己乳化組成物
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6057289A (en) 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
CZ20013162A3 (cs) * 1999-12-08 2002-06-12 Pharmacia Corporation Prostředky obsahující inhibitor cyklooxygenasy-2 mající rychlý nástup terapeutického účinku
NZ513964A (en) * 1999-12-08 2004-01-30 Pharmacia Corp Solid-state form of celecoxib having enhanced bioavailability
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
WO2002036110A2 (en) 2000-10-31 2002-05-10 Boehringer Ingelheim Pharmaceuticals, Inc. Oral self-emulsifying formulations of pyranone protease inhibitors
CZ20033341A3 (cs) 2001-06-21 2004-10-13 Pfizeráproductsáinc Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
US20030073609A1 (en) * 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
WO2004000284A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
IL164163A0 (en) 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
US6689382B2 (en) * 2002-05-15 2004-02-10 Procaps S.A. Soft shell gelatin capsules containing non-steroidal anti-inflammatories
EP1706098A4 (en) * 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICELLAR SYSTEMS SUITABLE FOR THE DELIVERY OF LIPOPHILIC OR HYDROPHOBIC COMPOUNDS
CA2647533A1 (en) 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
EP1961412A1 (en) 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Self-microemulsifying drug delivery systems
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
WO2009063367A1 (en) * 2007-11-15 2009-05-22 Pfizer Products Inc. Dosage forms comprising celecoxib providing both rapid and sustained pain relief
EP2311446A1 (en) * 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising Tramadol and Celecoxib in the treatment of pain
EP2340819A1 (en) * 2009-12-23 2011-07-06 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising venlafaxine and celecoxib in the treatment of pain
WO2012037328A2 (en) * 2010-09-17 2012-03-22 Maine Natural Health, Inc. Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof
KR101413846B1 (ko) * 2012-04-12 2014-06-30 주식회사 종근당 ４－［５－（４－메칠페닐）－３－（트리플루오로메칠）피라졸－１－일］벤젠술폰아미드 화합물 함유 액상 조성물
KR101455901B1 (ko) * 2012-05-04 2014-11-03 성균관대학교산학협력단 세레콕시브 및 폴록사머를 포함하는 공융 혼합물
KR20140100170A (ko) * 2013-02-05 2014-08-14 에스케이케미칼주식회사 셀레콕시브 경구투여용 조성물
MX349193B (es) 2013-08-27 2017-07-18 Alparis Sa De Cv Capsula con contenido liquido con un antiinflamatorio.
EP3104840B8 (en) * 2014-02-11 2019-07-10 Latitude Pharmaceuticals Inc. Parenteral compositions of celecoxib
US20150342893A1 (en) * 2014-05-29 2015-12-03 Sigmoid Pharma Limited Celecoxib formulations useful for treating colorectal cancer
CN107847437B (zh) * 2015-05-28 2024-03-26 瑞迪博士实验室有限公司 用于治疗疼痛的塞来昔布口服组合物
AU2016270504A1 (en) * 2015-05-29 2017-12-14 Codadose Incorporated Liquid formulations of celecoxib for oral administration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078724A1 (en) * 2000-04-18 2001-10-25 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2
WO2004047752A2 (en) * 2002-11-26 2004-06-10 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
WO2010150144A2 (en) * 2009-06-25 2010-12-29 Wockhardt Research Centre Low dose pharmaceutical compositions of celecoxib

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Formulation Design of Self-Microemulsifying Drug Delivery Systems for Improved Oral Bioavailability of Celecoxib";Natesan SUBRAMANIAN et al.;《Biol. Pharm. Bull.》;20041231;第27卷(第12期);第1993-1999页 *
"NIR-labeled perfluoropolyether nanoemulsions for drug delivery and imaging";Claire E. O’Hanlon et al.;《Journal of Fluorine Chemistry》;20120215;第137卷;第27-33页 *
"Topical delivery of celecoxib using microemulsion";NATESAN SUBRAMANIAN et al.;《ACTA POLONIAE PHARMACEUTICA-DRUG RESEARCH》;20041231;第61卷(第5期);第335-341页 *
Zvonar et al.."The Influence of Microstructure on Celecoxib Release from a Pharmaceutically Applicable System: Mygliol 812®/Labrasol®/Plurol Oleique®/Water Mixtures".《Acta Chim. Slov.》.2009,第56卷 *

Also Published As

Publication number Publication date
RU2017144574A3 (cg-RX-API-DMAC7.html) 2019-07-17
KR20180012277A (ko) 2018-02-05
US9949990B2 (en) 2018-04-24
US20170119798A1 (en) 2017-05-04
EA038013B1 (ru) 2021-06-23
US9572819B2 (en) 2017-02-21
US20180008619A1 (en) 2018-01-11
CN114209707A (zh) 2022-03-22
US20220241298A1 (en) 2022-08-04
US10376527B2 (en) 2019-08-13
WO2016191744A8 (en) 2018-01-25
EP3302429A1 (en) 2018-04-11
CA2987272C (en) 2019-08-20
JP2018516266A (ja) 2018-06-21
US20160346301A1 (en) 2016-12-01
US9795620B2 (en) 2017-10-24
CA2987272A1 (en) 2016-12-01
WO2016191744A1 (en) 2016-12-01
MX2017015238A (es) 2018-02-19
CN107847437A (zh) 2018-03-27
US20180200271A1 (en) 2018-07-19
US10799517B2 (en) 2020-10-13
AU2019203815A1 (en) 2019-06-20
JP6605047B2 (ja) 2019-11-13
US20180200270A1 (en) 2018-07-19
CN117547528A (zh) 2024-02-13
BR112017025445A2 (pt) 2018-08-07
KR101994129B1 (ko) 2019-06-28
NZ737561A (en) 2019-08-30
AU2016267685A1 (en) 2017-12-07
RU2017144574A (ru) 2019-06-28
EA201792530A1 (ru) 2018-10-31
MX384044B (es) 2025-03-14
RU2708254C2 (ru) 2019-12-05
US20190224219A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
CN107847437B (zh) 用于治疗疼痛的塞来昔布口服组合物
ES2968011T3 (es) Nuevas formulaciones de cannabinoides
US20250127714A1 (en) Oral composition of celecoxib for treatment of pain
US20180085308A1 (en) Sustained release cannabinoid formulations
CN108348475A (zh) 处于液体剂型的多层药学活性化合物释放微粒
NZ566117A (en) Oral suspension of prednisolone acetate
CA2993612A1 (en) Methods of treatment using cadotril compositions
US20180250262A1 (en) Sustained release cannabinoid formulations
RU2795918C1 (ru) Пероральная композиция целекоксиба для лечения боли
CN110115766B (zh) 一种含有氟比洛芬酯的复方制剂及其制备方法
BR112017025445B1 (pt) Composição oral de celecoxibe para tratamento da dor
CA3003120C (en) Cannabinoid formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant